Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine with concurrent radiotherapy for HBV-infected primary liver cancer
ChiCTR-TRC-10001100Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of telbivudine in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Liver function 12 weeks after radiotherapy. Started Feb 2010; status: completed.
02
Drugs
telbivudine
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR-TRC-10001100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001100.